On May 9, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024. The company currently has 14 clinical stage programs, with 10 of them being wholly owned. We expect a total of 18 clinical programs by the year end. For the next few months, Arrowhead will be hosting monthly webinars to focus on different disease areas and the company's candidates in those areas. In the near term, we anticipate results from the Phase 3 PALISADE trial to be presented at the June 25 cardiometabolic webinar with an NDA to be submitted by the end of 2024 and a potential commercial launch in 2025. Following the $450 million financing in January 2024, the company received a $50 million milestone payment from Royalty Pharma following completion of the Phase 3 OCEAN(a) trial of olpasiran, which is being conducted by Amgen.
